In-cell cryo-electron tomography reveals differential effects of type I and type II kinase inhibitors on LRRK2 filament formation and microtubule association
Open Access
- 27 July 2026
- journal article
- research article
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 15
Abstract
Mutations in leucine-rich repeat kinase 2 (LRRK2) are a leading contributor to developing familial and idiopathic Parkinson’s disease (PD). Most PD-causing LRRK2 mutations increase the kinase activity, leading to increased phosphorylation of Rab GTPases, disrupting vesicular trafficking, cytoskeletal dynamics, and autophagy. Under homeostatic conditions, the bulk of WT and PD-mutant LRRK2 is found in the cellular cytosol. However, exogenously expressed LRRK2 can form microtubule-associated filaments that have been shown to affect molecular transport along microtubules in vitro. While the physiological relevance of microtubule binding has not been established yet, inhibitors being designed and tested as therapeutics have been shown to either promote or prevent filament formation of LRRK2. In this study, we examine the localization and resulting molecular organization of hyperactive LRRK2-I2020T, a common PD mutant, in HEK 293FT cells treated with type I (MLi-2) or type II (GZD-824) kinase inhibitors. Treatment with a type I kinase inhibitor results in extensive LRRK2-I2020T decoration around microtubules and microtubule bundling. Stabilization of LRRK2-I2020T filaments by type I inhibitor treatment allowed us to build a full-length closed-kinase model of LRRK2-I2020T in its cellular environment. Conversely, treatment with a type II inhibitor resulted in minimal microtubule decoration by LRRK2-I2020T compared to type I inhibitor-treated cells. This study provides a structural framework for understanding how type I and type II kinase inhibitors differentially modulate LRRK2 filament formation, demonstrating that type I inhibitor treatment promotes a distinct filament architecture, whereas such assemblies are not observed with type II inhibitors.Keywords
All Related Versions
Funding Information
- Aligning Science Across Parkinson's (ASAP-000519)
- American Heart Association
- European Molecular Biology Organization (ALTF 871-2020)
- Jane Coffin Childs Memorial Fund for Medical Research
- Howard Hughes Medical Institute
- Michael J. Fox Foundation for Parkinson's Research
- National Science Foundation (DBI1920374)
- Jane Coffin Childs Memorial Fund for Medical Research
This publication has 60 references indexed in Scilit:
- A designed ankyrin-repeat protein that targets Parkinson’s disease-associated LRRK2Journal of Biological Chemistry, 2024
- UCSF ChimeraX : Tools for structure building and analysisProtein Science, 2023
- Small-molecule LRRK2 inhibitors for PD therapy: Current achievements and future perspectivesEuropean Journal of Medicinal Chemistry, 2023
- ArtiaX: An electron tomography toolbox for the interactive handling of sub‐tomograms in UCSF ChimeraXProtein Science, 2022
- Structural analysis of the full-length human LRRK2Cell, 2021
- Practical Approaches for Cryo-FIB Milling and Applications for Cellular Cryo-Electron Tomography2020
- The In Situ Structure of Parkinson’s Disease-Linked LRRK2Cell, 2020
- Pathogenic Parkinson’s disease mutations across the functional domains of LRRK2 alter the autophagic/lysosomal response to starvationBiochemical and Biophysical Research Communications, 2013
- A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2–q13.1Annals of Neurology, 2002
- Computer Visualization of Three-Dimensional Image Data Using IMODJournal of Structural Biology, 1996